Меню
Идёт набор NCT04968834

Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

— Наблюдательное Leukemia Myelodysplastic Syndromes Myeloproliferative Syndrome

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Genomic profiling.
Кому может быть актуально
Состояния в реестре: Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndrome. Базовые параметры: до 30 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Protocol For Genomically Profiling, Collecting, Archiving and Distributing Blood and Bone Marrow Specimens From Children and Young Adults With Hematologic Malignancy

Обзор

This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others. The genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a previous clinical procedure or will be obtained at the time of a scheduled clinical procedure. Studying the genetic information in the cells of these samples will provide information about the origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic assessments to be performed in the future.

Подробное описание

Pediatric patients with new diagnosis or relapsed/refractory acute leukemia, MDS/AML, chronic leukemia, myeloproliferative syndromes or myelodysplastic syndrome will be enrolled onto this study. At the time of enrollment, a sample of the leukemia will be submitted for genomic profiling using CLIA assay(s). This information will be returned to the treating oncologist. The study will collect follow up data on patient outcome and whether the genomic profiling influenced treatment.

It is expected that about 100 people each year will take part in this research study at 8 medical centers in the United States

Вмешательства

  • Генная терапия Genomic profiling
    Genomic profiling using CLIA assay

Первичные конечные точки

  • Number of Patients Enrolled for Genomic Profiling-Pediatric Leukemia [Срок оценки: 3 Years]
Вторичные конечные точки (1)
  • Number of Patients Enrolled for Genomic Profiling-New Diagnosis [Срок оценки: 3 Years]

Критерии участия

Критерии включения

  • Age: birth to < 30 years of age
  • Diagnosis:

\-- Patient with acute leukemia, chronic leukemia, MDS/AML, myelodysplastic syndrome or myeloproliferative syndromes. Disease can be newly diagnosed or relapsed/refractory.

  • Pathology Criteria:

\-- Histologic confirmation of leukemia or myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS) at the time of diagnosis or recurrence

  • Specimen Criteria:
  • Sufficient sample available for genomic profiling OR bone marrow aspirate/blood draw planned for clinical care which is anticipated to allow collection of minimum specimen for testing (See Section 6.1 for description of specimen requirements)

Критерии исключения

\- Insufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence (See Section 6.1); or bone marrow evaluations NOT planned for clinical care; or peripheral blast percentage <20%, or clinical blood draw not planned

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

США · 8 центров
  • Connecticut Children's Medical Center — Hartford
  • Maine Medical Center — Portland
  • Boston Children's Hospital — Boston
  • Dana Farber Cancer Institute — Boston
  • Dartmouth-Hitchcock — Lebanon
  • Albany Medical Center — Albany
  • Lifespan Cancer Institute — Providence
  • University of Vermont Medical Center — Burlington

Идентификаторы

NCT: NCT04968834 · 20-302

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗